Know Cancer

or
forgot password

FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer


Inclusion Criteria:



- Confirmed locally advanced or metastatic non-small cell lung cancer that is
unresectable

- At least 1 unirradiated target lesion measurable by RECIST

- Adequate hematologic, renal and hepatic function

- ECOG 0,1

- Able to understand and sign an Informed Consent

Exclusion Criteria:

- Presence of brain metastases, unless the patient received brain irradiation,
including adequate stereotactic radiosurgery, at least 4 weeks prior to
randomization, and is stable, asymptomatic, and off steroids for at least 3 weeks
prior to randomization

- Received prior systemic anti-cancer therapy for NSCLC

- History of allergic reactions to compounds of similar chemical or biologic
composition to talactoferrin or the chemotherapy drugs

- Any gastrointestinal tract disease or other medical condition resulting in the
inability to take oral medications

- History of other malignancies except: (i) adequately treated basal or squamous cell
carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine
cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other
curatively treated solid tumor with no evidence of disease for ≥5 years

- Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart
failure

- Serious active infection

- Psychiatric illness/social situations that would limit study compliance

- Other uncontrolled serious chronic disease or conditions that in the investigator's
opinion could render compliance or follow-up in the protocol problematic

- Concurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or
previous radiotherapy at the indicator sites (the sites that are to be followed for
determination of a response)

- Concurrent systemic corticosteroid therapy within 4 weeks prior to randomization,
except prophylactic use of steroids prior to paclitaxel administration

- Known HIV positive or on active anti-retroviral therapy

- Known Hepatitis B surface antigen positive or hepatitis C positive

- Receipt of any investigational medication within 4 weeks prior to randomization

- Pregnant or lactating patients, or fertile female patients with a positive pregnancy
test, or fertile female patients unwilling to use adequate contraception during
treatment and for 30 days after completion of treatment

- Sexually active male patients unwilling to practice contraception while participating
on the study and up to 30 days after completion of treatment

- Legal incapacity or limited legal capacity, unless authorization is granted by a
legal guardian

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival

Outcome Time Frame:

After the occurence of the required number of events

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

LF-0208

NCT ID:

NCT00706862

Start Date:

February 2009

Completion Date:

March 2016

Related Keywords:

  • Non Small Cell Lung Cancer
  • Non small cell lung cancer
  • Talactoferrin
  • Dendritic cell recruiter and activator
  • DCRA
  • Immunomodulatory agent
  • Lactoferrin
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Rush University Medical CenterChicago, Illinois  60612-3824
Montefiore Medical CenterBronx, New York  10467-2490
City of HopeDuarte, California  91010
Duke University Medical CenterDurham, North Carolina  27710
Chattanooga Oncology and Hematology AssociatesChattanooga, Tennessee  37404
Sarah Cannon Research InstituteNashville, Tennessee  37203